Psoriatic Arthritis

FDA approves guselkumab for psoriatic arthritis
July 16, 2020

Guselkumab becomes the first IL-23 inhibitor approved for treatment of psoriatic arthritis by the U.S. Food and Drug Administration (FDA) following positive phase 3 results from two trials investigating the safety and efficacy of the drug.

Psoriasis biosimilar approved by FDA
July 15, 2020

The U.S. Food and Drug Administration has approved Mylan and Fujifilm Kyowa Kirin Biologics’ adalimumab-fkjp as a biosimilar to AbbVie’s adalimumab for a variety of inflammatory disease including plaque psoriasis and psoriatic arthritis.

AbbVie seeks approval of upadacitinib in U.S., Europe for psoriatic arthritis
June 03, 2020

AbbVie announces they have filed applications with the U.S. FDA and EMA for the approval of the JAK inhibitor upadacitinib for the treatment of adult active psoriatic arthritis.